Nasdaq-listed 111, a Chinese language healthcare platform, has entered right into a strategic cooperation settlement with Jiangsu-based drug R&D agency Suzhou Zelgen Biopharmaceuticals Co. to construct a digital platform for liver most cancers sufferers.
WHAT IT DOES
111 operates an web hospital providing digital well being consultations, an digital prescription service, and a affected person administration service. It additionally runs certainly one of China’s largest retail pharmacy networks serving over 320,000 pharmacies, in addition to a medication market the place pharmacies can supply merchandise. Furthermore, 111 gives an omnichannel commercialisation platform for pharmaceutical corporations.
WHY IT MATTERS
111 claims that its upcoming on-line illness administration platform will supply liver most cancers sufferers with built-in providers, together with on-line consultations and knowledge on ailments, medicines and therapies.
Moreover, this newest partnership will see Zelgen’s flagship product Zeprosyn – a drug for treating unresectable hepatocellular carcinoma, marketed by way of the platform.
Liver most cancers is the second main reason for most cancers deaths in China. Knowledge from the WHO’s Worldwide Company for Analysis on Most cancers exhibits that liver most cancers accounts for about 410,000 new most cancers circumstances in China final yr, inflicting round 390,000 deaths.
THE LARGER TREND
In Could, 111 additionally made the same cope with one other biotech agency, BeiGene, to launch an internet oncology administration platform leveraging its web hospital capabilities.
111 mentioned it has up to now made 360 direct partnerships with pharma corporations, resembling Eli Lilly and Bayer Healthcare.
ON THE RECORD
“The cooperation with Zelgen within the area of liver most cancers is a crucial deployment of our digital platform in well being administration providers directed towards a number one reason for most cancers dying in China. By harnessing the facility of the web, we are able to break the constraints of time and house, and this new digital platform will deliver collectively specialists and sufferers on-line to effectively perform diagnoses, therapy training, follow-up visits and prescription renewals. These capabilities not solely broaden the service radius of docs but in addition assist medicines like Zeprosyn attain extra sufferers,” Dr Yu Gang, co-founder and govt chairman of 111, said.
“Via this partnership, we will make the most of 111’s on-line prognosis, therapy, multi-channel platform and well being administration providers to additional enhance the supply of latest medication and, in flip, present better advantages to sufferers,” Zelgen Chairman and Normal Supervisor Dr Sheng Zelin additionally commented.